AsymBio
Shanghai, China
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (2)
○ EMA GMP
○ MHRA GMP
Quick Facts: AsymBio
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Shanghai, China
- Modalities
- Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, ADC, Bioconjugates (NDC, RDC, AOC, PDC, BsADC), Plasmid DNA, mRNA, Fill-Finish
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About AsymBio
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesMonoclonal Antibody, Bispecific Antibody, Recombinant Protein, ADC, Bioconjugates (NDC, RDC, AOC, PDC, BsADC), Plasmid DNA, mRNA, Fill-Finish
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (8 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press2 articles
Broad modality coverage (8 modalities)
Recent News 2 articles
AsymBio Showcases Comprehensive Conjugation Toolbox to - GlobeNewswire
AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities - PR Newswire
Frequently Asked Questions About AsymBio
What is AsymBio's CDMO Signal Score?
AsymBio has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating AsymBio for a manufacturing program?
Use the free AI matchmaker to compare AsymBio against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Catalent
Bagsværd, Denmark (operating under Novo Holdings)
Signal Score: 76.5
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
Signal Score: 75.1
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Lonza
Basel, Switzerland
Signal Score: 78.2
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein
Samsung Biologics
Incheon, South Korea
Signal Score: 68.5
Monoclonal Antibody, Recombinant Protein, ADC, mRNA
EirGenix
Zhubei City, Hsinchu County, Taiwan
Monoclonal Antibody, Bispecific/Polyclonal Antibody, Recombinant Protein, ADC, Biosimilars, Plasmid DNA